Supernus Pharmaceuticals SUPN Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $129.9M+87.4% | $69.33M-7.6% | $75.05M-19.4% | $93.12M-54.2% | ||
| $187.8M+32.2% | $142.08M-1.4% | $144.16M-12.9% | $165.5M+11.1% | ||
| $30.1M— | $0-100% | $77.41M-15.4% | $91.54M+6.5% | ||
| $644.18M-6.1% | $686.07M+39.1% | $493.11M-32.8% | $734.15M+22.0% | ||
| $10.53M-8.8% | $11.55M-14.7% | $13.53M-10.8% | $15.17M-10.5% | ||
| $124.88M+6.7% | $117.02M0.0% | $117.02M0.0% | $117.02M-0.4% | ||
| $569.46M+9.1% | $521.91M-13.0% | $599.89M-14.6% | $702.46M-10.5% | ||
| $1.45B+6.2% | $1.37B+7.1% | $1.28B-25.0% | $1.7B+0.8% | ||
| $338.17M+15.7% | $292.4M+0.8% | $290.2M-57.8% | $687.96M+118% | ||
| $31.26M-90.6% | $332.34M-6.7% | $356.16M-56.4% | $816.3M-6.5% | ||
| 130M+232,043% | 56K+1.8% | 55K+1.9% | 54K+1.9% | ||
| $517.88M-6.9% | $556.43M+15.3% | $482.56M+0.3% | $481.25M+26.7% | ||
| $1.06B+2.5% | $1.04B+12.4% | $921.52M+4.0% | $886.2M+8.6% | ||
| $1.45B+6.2% | $1.37B+7.1% | $1.28B-25.0% | $1.7B+0.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Supernus Pharmaceuticals cover its short-term obligations?
- Its current ratio is 1.96 — current assets exceed current liabilities.
- Where does Supernus Pharmaceuticals's balance sheet data come from?
- Every line is extracted from Supernus Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.